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Cancer progression depends on both cell-intrinsic
processes and interactions between different cell
types. However, large-scale assessment of cell type
composition and molecular profiles of individual
cell types within tumors remains challenging. To
address this, we developed epigenomic deconvolu-
tion (EDec), an in silico method that infers cell type
composition of complex tissues as well as DNA
methylation and gene transcription profiles of con-
stituent cell types. By applying EDec to The Cancer
Genome Atlas (TCGA) breast tumors, we detect
changes in immune cell infiltration related to patient
prognosis, and a striking change in stromal fibro-
blast-to-adipocyte ratio across breast cancer sub-
types. Furthermore, we show that a less adipose
stroma tends to display lower levels of mitochondrial
activity and to be associated with cancerous cells
with higher levels of oxidative metabolism. These
findings highlight the role of stromal composition in
the metabolic coupling between distinct cell types
within tumors.
INTRODUCTION
Molecular profiling of breast tumors has led to their categori-
zation into different subtypes with distinct risks and underlying
biology. Of particular interest is the classification into five
intrinsic subtypes, which can be performed using the prediction
analysis of microarray 50 (PAM50) classifier (Parker et al., 2009).
However, most molecular-profiling studies to date have been
performed on bulk tissue samples, ignoring the complexity of
the breast tissue, with its multiple cell types and the interactionsCell Repor
This is an open access article undbetween them. Valuable evidence for the significance of hetero-
typic interactions comes from the study of cell type composition
of tumors, as exemplified by the prognostic value of immune
cell infiltration (Coussens et al., 2013; Liu et al., 2014) and of epi-
genomic (Hu et al., 2005) and transcriptomic (Finak et al., 2008)
perturbations within stromal cells (Tlsty and Coussens, 2006).
Laser capture microdissection (LCM), cell sorting, and other
physical methods to isolate cell types from solid tumors for
molecular profiling are technically challenging, and severely limit
throughput (Debey et al., 2004). A number of methods for in silico
deconvolution have been developed to address this problem us-
ing as input gene expression profiles (Aran et al., 2015; Gentles
et al., 2015; Houseman and Ince, 2014; Kuhn et al., 2011; Li
and Xie, 2013; Newman et al., 2015; Shen-Orr et al., 2010; Venet
et al., 2001; Yoshihara et al., 2013; Zhong et al., 2013) and, more
recently, DNAmethylation profiles (Houseman et al., 2012, 2014,
2016; Zheng et al., 2014; Zou et al., 2014; Rahmani et al., 2016) of
tissue homogenates. However, the ability of these methods to
infer cell type composition of solid tumors and interpret the
states of constituent cell types is limited, thus hampering the
study of cellular states and cellular interactions within the tumor
microenvironment.
To address this gap, we developed epigenomic deconvolution
(EDec), a deconvolution method based on a heuristic for con-
strained matrix factorization using quadratic programming. The
deconvolution is based on cell-type-specific patterns of DNA
methylation. Such patterns are acquired during normal cellular
differentiation, maintained through cell division, and serve as
chemically stable cellular markers. We reasoned that methyl-
ation profiles would be more amenable to deconvolution than
gene expression due to their linearity, measurement within the
complete (0–1) dynamic range, and technology independence
(including both bisulfite sequencing and array platforms).
Previous methylation-based deconvolution methods either
make direct use of reference methylation profiles of constituent
cell types (Houseman et al., 2012) or ignore such referencests 17, 2075–2086, November 15, 2016 ª 2016 The Author(s). 2075
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
(Houseman et al., 2014, 2016; Rahmani et al., 2016; Zou et al.,
2014). Highly accurate reference methylation profiles, essential
for reference-based deconvolution approaches, are unavailable
for many solid tissues, arguing for a reference-free approach.
However, reference methylation profiles from representative
cell lines are available and can provide valuable information if
used to improve inference while minimizing bias. Toward this
goal, EDec uses relevant reference information in indirect
ways to minimize bias. First, it uses references to identify sets
of loci that are likely to exhibit variation in methylation levels
across constituent cell types of a given tissue (feature selection),
while taking a reference-free approach to the deconvolution
problem itself. Second, it identifies constituent cell types by
comparing their deconvoluted molecular profiles to reference
profiles.
EDec consists of three stages (0, 1, and 2; Figure 1). Starting
withmethylationprofilesof tumor homogenatesover loci selected
basedon referencemethylationprofiles (Figure1A, stage0), EDec
estimates both cell type proportions and methylation profiles of
constituent cell types using an reference-free approach (Fig-
ure 1A, stage 1) similar to previous reference-free techniques
(Gaujoux and Seoighe, 2012; Houseman et al., 2016). The pro-
portion estimates are then used as a ‘‘key’’ to deconvolute
gene expression profiles of constituent cell types (Figure 1A,
stage 2).
EDec proof-of-concept experiments were performed using
both Illumina methylation arrays and RainDance Technologies’
ThunderStorm bisulfite sequencing (BS-seq) (Komori et al.,
2011; Paul et al., 2014) targeted bisulfite sequencing. The
method is validated using both computer simulations and
profiling experiments on prepared cell mixtures. By applying
EDec to the breast cancer datasets generated by The Cancer
Genome Atlas (TCGA) (Cancer Genome Atlas Network, 2012),
we predict cellular proportions andmethylation states of constit-
uent cell types within breast tumors as well as infer changes
in gene expression within each constituent cell type. Such pre-
dictions were largely confirmed by comparisons with cell type
composition estimates based on H&E staining, and by com-
parison against gene expression profiles of specific cell types
isolated through LCM. We show that cancerous epithelial cells
exhibit methylomes distinct from those of normal epithelium.
EDec also replicates the previously reported association be-
tween increased immune cell infiltration in triple-negative breast
cancer and better prognosis (Adams et al., 2014). We further
detect expression changes that are highly consistent with known
hallmarks of cancer, and with known roles of specific cell types
within breast cancer. Last, we observe that the degree of stromal
adiposity across breast cancer subtypes predicts the pattern of
metabolic coupling observed between cancer epithelium and
stroma.
RESULTS
Epigenomic Deconvolution Method
The first stage of EDec (Figure 1A, stage 1) performs constrained
matrix factorization to find cell type-specific methylation profiles
and constituent cell type proportions that minimize the Euclidian
distance between their linear combination and the original matrix2076 Cell Reports 17, 2075–2086, November 15, 2016of tissue methylation profiles (Figure 1B). The minimization algo-
rithm involves an iterative procedure that, in each round, alter-
nates between estimating constituent cell type proportions and
methylation profiles by solving constrained least-squares prob-
lems through quadratic programming. Theminimization problem
is made tractable by the constraints that methylation measure-
ments (beta values) and cell type proportions are numbers in
the [0, 1] interval, and that cell type proportions within a sample
add up to 1. These constraints restrict the space of possible so-
lutions, thus making it possible for the local iterative search to
reproducibly find a global minimum and an accurate solution.
One key requirement for EDec is that cell type proportions vary
across samples. A second requirement is that there must be
significant differences across constituent cell type methylation
profiles. The latter requirement can be met by providing EDec
with loci expected to vary in methylation levels across constitu-
ent cell types (Figure 1A, stage 0).
Similar to how tissue methylation profiles are modeled, tissue
gene expression profiles can also be modeled by the linear com-
bination of the expression profiles of its constituent cell types.
However, due to the less constrained nature of gene expression
measurements ([0,N]) versusmethylationmeasurements ([0, 1]),
the same reference-free approach used in stage 1 is not as
effective for gene expression deconvolution. Therefore, instead
of using that approach, when both DNA methylation and gene
expression profiles are available for the same set of samples
(e.g., from the same tissue homogenate), EDec-stage 2 uses
the cell proportions estimated in stage 1 as a fixed input when
estimating the average gene expression profiles of constituent
cell types through a constrained least-squares fit using quadratic
programming with solutions constrained to [0, N] (Figure 1A,
stage 2, and Figure 1C).
Validation using in Silico Mixtures of Methylation
Profiles Derived from Breast Cancer-Related Cell Lines
We first validated the core EDec algorithm (stage 1) on simulated
mixtures of experimentally derived DNA methylation profiles
(nine cell lines: six breast cancer, one normal breast epithelial,
one immune, and one cancer-associated fibroblast [CAF]).
Among the 1,000 target genomic regions included in this breast
cancer methylation-focused panel (Table S2), 149 exhibited
particularly distinct methylation patterns across different breast
cell types (based on reference epigenomes) (Kundaje et al.,
2015) and were used in EDec-stage 1. The simulation dataset
consisted of 100 mixtures, each composed of four cell types
(one breast cancer cell line, one normal mammary epithelial
cell type, one stromal cell type, and one immune cell type). About
one-half of the simulated mixtures contained on average higher
levels of breast cancer (60%) and immune cell types (20%),
representing distributions observed in tumor samples such as
those in the TCGA dataset. To simulate the presence of different
breast cancer subtypes, different simulated mixtures had a
different cancerous epithelium constituent. Specifically, the
breast cancer cell type for each mixture was chosen randomly
from the set of six breast cancer cell lines. Simulated normal
breast contained higher than average levels of normal epithelial
(60%) and stromal cell types (30%). To better represent real
samples, random noise was introduced into the methylation
Figure 1. Description of the EDec Method
(A) The EDecmethod has twomain stages (stages 1 and 2), preceded by a preparation stage (stage 0). In stage 0, a set of reference methylation profiles is used to
select a set of genomic loci or array probes with distinct methylation levels across groups of references representing different constituent cell types. Methylation
profiles of complex tissue samples over the set of loci/probes selected in stage 0 are used as the input for the stage 1 of the EDec method. In stage 1, EDec
estimates both the average methylation profiles of constituent cell types and the proportions of constituent cell types in each input sample using an iterative
algorithm for constrained matrix factorization using quadratic programming. Stage 2 of EDec takes as input the gene expression profiles of the same tissue
samples profiled for DNA methylation, as well as the proportions of constituent cell types for those samples, estimated in stage 1, and outputs the gene
expression profiles of constituent cell types.
(B) Representation of the model associated with stage 1 of EDec method.
(C) Representation of the model used for gene expression deconvolution in stage 2 of the EDec method.
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profiles across all samples (Supplemental Experimental Proced-
ures). We applied EDec to this dataset assuming nine different
cell types in the model (six possible breast cancer cell lines,
one normal epithelial, one stromal, and one immune). EDec
accurately estimated DNA methylation profiles (r = 0.982; Fig-
ure 2A) and proportions (r = 0.983) for all constituent cell types
(Figure 2B).
Validation on Cell Line Mixtures Profiled by Targeted
Bisulfite Sequencing
We next validated EDec on cellular mixtures prepared in vitro.
Specifically, we profiled 10 samples using targeted bisulfite
sequencing and applied EDec using the set of 149 loci selected
in EDec-stage 0. Four of the 10 samples were pure cells lines,
including the following:MCF-7, HMEC (humanmammary epithe-
lial cells), a CAF cell line, andCD8+ cytotoxic T cells. The other six
samples consisted of three pairwise combinations (MCF-7/
HMEC, MCF-7/T cells, and MCF-7/CAF), each in two propor-
tions (75%:25% and 95%:5%). There was a strong concordance
between the EDec estimated and the true proportions (r = 0.996;
Figure 2C). In addition, the estimated methylation profiles for the
four different cellular fractions closely matched the methylation
profiles of cells used to create themixtures (r = 0.998; Figure 2D).
Validation on Breast Tumor Samples Profiled by
Targeted Bisulfite Sequencing
We next generated DNA methylation profiles for 31 breast
tumors and 8 normal breast samples using targeted bisulfite
sequencing. We applied EDec, assuming six constituent cell
types (Supplemental Experimental Procedures), and asked
how similar the estimated methylation profiles were to a set of
external reference methylation profiles (Figure 2E). Three of the
six estimated methylation profiles were most similar to one of
the reference breast cancer cell lines. The three remaining pro-
files had particularly high correlation with themethylation profiles
of either CD8+ cytotoxic T cells, CAF cell line, or the HMEC cell
line. This indicates that EDec identifies three components that
explain the diversity of cancerous epithelial cells in those sam-
ples, whereas the other three components correspond to an
immune fraction, a fibroblast/stromal fraction, and a normal
epithelial fraction.
To further validate EDec, clinical pathologist evaluations of cell
type composition were obtained for 29 of the 39 samples based
on H&E staining. The pathologist estimated proportions for
cancerous epithelial, normal epithelial, stromal, and immune
fractions. Since the EDec method had proportion estimates for
three different cancer epithelial fractions, we combined the pro-
portions for those three fractions to make the two techniques
comparable. Despite observing good consistency for the cancer
epithelial and immune fractions, we observed low correlation for
the normal epithelial and stromal fractions. We reasoned that the
low correlation may be explained by extensive epithelial-mesen-
chymal transitions that may blur the boundary between epithe-
lial and stromal cells. We therefore modified the analysis by
combining proportion estimates of normal epithelial and stromal
components and examined concordance of EDec and H&E
proportion estimates for three fractions (cancerous epithelial,
normal epithelial/stromal, and immune). The estimates were2078 Cell Reports 17, 2075–2086, November 15, 2016highly concordant for all three cell type fractions (r = 0.74,
p value < 1015; Figure 2F). The highest correlation was for the
immune fraction (0.78) and the lowest for cancerous epithelial
fraction (0.67). The concordance between these two techniques
indicates that EDec’s estimates of proportions and methylation
profiles correspond to real cell types and are not just general
components that explain variability in the methylation dataset.
Deconvolution of Breast Tumors from the TCGA
Collection Confirms the Role of Immune Response
in Tumor Progression
We next applied EDec to deconvolute DNA methylation profiles
of 1,061 breast tumors and 123 adjacent normal breast samples
generated using Infinium HumanMethylation arrays by TCGA
(Cancer Genome Atlas Network, 2012). We selected 391 infor-
mative loci (EDec-stage 0) from 45 reference DNA methylation
profiles gathered from the NCBI GEO archive for the following
four relevant cell types: cancer epithelial (25), normal epithelial
(3), stromal (9), and immune (8) (Figure 3A) (Supplemental Exper-
imental Procedures).
EDec-stage 1 (Figure 1A) was then applied to the TCGA DNA
methylation data over the 391 probes, assuming 4–15 constitu-
ent cell types. Reference methylation profiles (20) were added
to the TCGA dataset to improve stability of convergence (Sup-
plemental Experimental Procedures and Figure S5). Based on
model reproducibility and goodness of fit (Supplemental Exper-
imental Procedures), we chose themodel with eight cell types for
all further analyses. We generated heat maps of correlations be-
tween the eight EDec-estimated methylation profiles and each
GEO reference methylation profile (Figure 3B). The correlations
suggest that EDec identified methylation profiles correspond-
ing to one immune, one stromal, one normal epithelial, and five
different cancerous epithelial components.
DNA methylation profiles were also generated for nine of
the TCGA samples using targeted bisulfite sequencing. This
allowed us to compare EDec-estimated proportions for those
samples based on sequencing data, in the context of 39 breast
tissue samples profiled by bisulfite sequencing, versus those
estimates based on arrays in the context of 1,184 TCGA sam-
ples (Figure 3C). Estimated proportions were highly correlated
(r = 0.88), suggesting that EDec operates independently of
the methylation profiling method. EDec and pathologist (H&E
staining) proportion estimates were also consistent (r = 0.90)
(Figure 3D).
Consistent with expectations, EDec predicts normal breast
samples to have negligible proportions of cancerous epithelial
cells, whereas in breast tumors those cell types are generally
the ones with highest proportions (Figure 3E). We also observe
that the cancerous cell fraction of the different breast cancer
samples is explained by a different combination of the five
cancerous epithelial components, with one of them typically be-
ing dominant. Grouping tumor samples based on the dominant
cancer epithelial component showed some concordance with
their PAM50 classification (Parker et al., 2009). In particular,
basal-like samples were nearly all in the same EDec-defined
group (Figure 3E, red box). We further investigated methylation
heterogeneity of the epithelial fraction over the 391 chosen
probes within and between tumor subtypes (Supplemental
Figure 2. EDec Validation on Simulated
Mixtures, Experimental Mixtures, and Solid
Tumors
(A) Estimated versus true methylation levels for
each constituent cell type and locus involved in the
simulated mixtures dataset.
(B) Estimated versus true proportions for each con-
stituent cell type in each of the samples involved in
the simulated mixtures dataset.
(C) Estimated versus true methylation levels for
each constituent cell type and locus profiled in the
experimental mixtures dataset.
(D) Estimated versus true proportions for each
constituent cell type in each of the samples pro-
filed in the experimental mixtures dataset.
(E) Heat map representing the level of correlation
between the estimated methylation profiles from
the application of EDec to the targeted bisulfite-
sequencing dataset and the reference methylation
profiles. Red boxes indicate the highest level of
correlation for each estimated methylation profile.
The estimated methylation profiles were labeled
as cancer epithelial, normal epithelial, immune, or
stromal based on what reference methylation
profile was most correlated to each of them.
(F) Proportion of constituent cell types estimated
by EDec for samples in the targeted bisulfite-
sequencing dataset versus pathologist-estimated
proportions (H&E staining). Color key for all panels:
orange (MCF-7), blue (HMEC), green (CAF), and
red (T cell).Experimental Procedures and Figure S1). Luminal B tumors
had the most heterogeneous profiles, whereas normal breast
samples had the most homogeneous epithelial profile. Despite
having an intermediary level of heterogeneity, basal-like tumors
exhibited epithelial methylation profiles highly distinct from the
other breast tumor subtypes.
We also found that tumor subtypes differ significantly in the
degree of infiltration by either immuneor stromal cells (Figure S2).
Normal-like samples contained the highest median stromal pro-
portion (18%), and Luminal B tumors, the lowest (4%). Basal-like
tumors displayed the highest median degree of immune cell infil-
tration (21%), whereas Luminal B tumors again had the lowest
(7%). Normal breast tissue samples displayed a much higherCell Reportmedian proportion of stromal cells (37%)
than breast tumors (8%).
We next investigated whether the pre-
dicted immuneproportionwasassociated
with survival of basal-like breast cancer
patients. Indeed, patients with greater
than 20% immune cell infiltration survived
significantly longer (p < 0.01) than those
with less than 20% (Figure 3F), consistent
with previous microscopy-based evalua-
tion of immune cell infiltration (Adams
et al., 2014).We also investigatedwhether
immune infiltration levels in adjacent
normal tissuewere related to immune infil-
tration levels in the matched tumor sam-ple. No such correlation was observed, indicating that immune
infiltration of tumors is not dependent on the amount of immune
cells in the surrounding normal tissue (Figure S2).
Deconvolution of RNA-Sequencing Profiles of Breast
Tumors from the TCGA Collection Reveals Cell Type-
Specific Tumorigenic Perturbations with the Tumor
Microenvironment
Given the availability of both mRNA-sequencing and DNA
methylation profiles for the TCGA breast samples, we applied
EDec-stage 2 to estimate gene expression profiles of constituent
cell types. EDec-stage 2 was independently applied to six sub-
sets of the 1,114 TCGA expression profiles, corresponding tos 17, 2075–2086, November 15, 2016 2079
Figure 3. Analysis of DNA Methylation Profiles of Breast Tumors Samples from the TCGA Collection using EDec
(A) Heat map representing the methylation levels over the chosen set of array probes for the reference methylation profiles.
(B) Heat map representing the correlation between the methylation profiles estimated by EDec and the reference methylation profiles. Red boxes indicate the
highest correlation for each estimated methylation profile.
(C) Scatterplot of EDec cell type proportion estimates for nine TCGA samples based on targeted bisulfite sequencing (y axis) and microarray (x axis).
(D) Scatterplot between EDec and pathologist (H&E) estimates of proportions of constituent cell types for a subset (six samples) of the TCGA dataset for which
H&E staining-based estimates were available.
(E) EDec-estimated proportions of constituent cell types for samples in the TCGA dataset. Side bar represents separation of TCGA cancers samples into PAM50
expression subtypes. The red box highlights the samples best explained by the cancerous epithelial 2 profile, which are almost exclusively classified as basal-like.
(F) Kaplan-Meier plot indicating the significant difference in prognosis (p value < 0.01) for patients within the group of samples best explained by the cancer
epithelial 2 profile (red box in [F]; basal-like) with high versus low estimated immune cell type proportion. See also Figures S1 and S2.the five PAM50 subtypes (Luminal A [523 samples], Luminal
B [207], HER2-enriched [78], basal-like [173], normal-like [33])
(Parker et al., 2009), plus normal breast tissue samples (100).
We combined the eight EDec-stage 1-estimated proportions
(Figure 3E) into the following three cell type fractions: epithelial
(including five cancer epithelial and one normal epithelial), stro-
mal, and immune. Proportion estimates for those three cell types
were then used in EDec-stage 2 to estimate expression profiles
of epithelial, stromal, and immune cell types for each PAM50
subtype and normal breast.
EDec predicts epithelial-specific expression of ESR1, PGR,
and FOXA1 in Luminal A and Luminal B subtypes (Figure 4A),
consistent with previous reports (Toss and Cristofanilli, 2015).2080 Cell Reports 17, 2075–2086, November 15, 2016Due to poor model fit, as indicated by large error bars, cell-
type-specific expression could not be established for a
number of genes, ERBB2 within HER2-enriched tumors being
the most conspicuous example. The poor fit of the model for
that gene is due to its exceedingly high variance in expression
within epithelial cells of this tumor type (Figure S3). We can
show through simulations (Supplemental Experimental Pro-
cedures) that this effect is mitigated by increasing the number
of input breast cancer samples. We note that the large esti-
mated standard error provides a clear signal that cell type-
specific expression cannot be established for specific genes,
thus preventing erroneous conclusion suggested by high
mean values.
Figure 4. Cell Type-Specific Gene Expres-
sion
(A) Bar plots represent the estimated expression
profiles of 12 different genes within constituent cell
types for each of the breast cancer intrinsic sub-
types, as well as for the set of normal breast
(control) samples. Error bars represent estimated
standard error associated with each cell type
specific gene expression estimate.
(B) Summary of main enriched gene sets among
upregulated or downregulated genes between
cancer and normal breast in each cell type. See
also Figures S3 and S4.EDec predicts stroma-specific expression of vimentin (VIM), a
general mesenchymal cell marker (Kalluri and Zeisberg, 2006), in
normal breast and in all tumor subtypes. Conversely, the stroma-
specific expression of COL1A1, FAP, and FN1 is observed in tu-
mors, but not in normal breast (Figure 4A). That observation is
consistent with the activation of such genes in CAFs, the main
constituent of the tumor stroma (Kalluri and Zeisberg, 2006).Cell ReportEDec correctly predicts immune-spe-
cific expression of immune cell markers
(PTPRC, CD3G, CD8A, and CD4) in every
group of samples (Figure 4A). Note that
the CD8+ T cell marker CD8A shows
significantly higher expression in breast
cancers than in normal breasts, consis-
tent with observations that the immune
components of breast tumors contains
a larger proportion of CD8+ T cells
compared to the immune component of
normal breasts.
We next compared gene expression
profiles of the three tumor-constituent cell
types against the profiles of their normal
control counterparts. A gene set enrich-
ment analysis (Huang et al., 2009a,
2009b) was then performed on the result-
ing sets of differentially expressed genes.
Figure 4B summarizes the top gene set en-
richments for genes upregulated or down-
regulated in tumor cells compared the
normal controls (for full set of gene set en-
richments, see Table S1). The terms found
to be enriched in each of the sets of differ-
entially expressed genes are consistent
with knownhallmarks of cancer (sustaining
proliferative signaling, activating invasion
and metastasis, inducing angiogenesis,
deregulating cellular energetics, avoiding
immune destruction, etc.) and with the
known roles of each cell type within breast
tumors (e.g., ‘‘extracellular matrix remod-
eling’’ genes upregulated specifically in
stromal cells and ‘‘sustaining inflammation
in tumor’’ category in immune cells) (Hana-
han and Weinberg, 2011).We next sought to further validate EDec-stage 2 predictions
of differentially expressed genes against a previously published
dataset, in which gene expression profiling was performed on
epithelial and stromal components of matched invasive carci-
nomas and adjacent normal tissue, after LCM (Ma et al., 2009).
Despite the fact that the study did not separate out the immune
component, focused on the fibrous portion of the stroma (both ins 17, 2075–2086, November 15, 2016 2081
Figure 5. Switch from Adipose to Fibrous Stroma Influences the Metabolic Phenotype of the Tumor
(A) Enrichment of either OXPHOS or GLYCOLYSIS gene sets (hallmark gene sets MSigDB [Liberzon et al., 2015]) among those upregulated or downregulated in
epithelial or stromal cells of breast cancer. Cell-type-specific differential expression analysis was performed with either by applying EDec to TCGA dataset, or in
the LCM dataset. Dashed lines represent a p value of 0.01.
(B) Estimated stromal expression of either adipocyte or CAF markers across breast cancer subtypes.
(C) Representative H&E staining images of matched tumor and normal breast samples from TCGA (TCGA-BH-A0B2).
(D) Histogram of correlations between stromal expression of OXPHOS genes and stromal expression of marker genes of either adipocyte or CAF across breast
cancer subtypes.
(E) Histogram of correlations between epithelial expression of OXPHOS genes and stromal expression of marker genes of either adipocyte or CAF across breast
cancer subtypes.normal breast and breast cancer), and used microarrays to
profile expression, we still observe significant overlaps between
the differentially expressed genes predicted by EDec and
those observed in the LCM dataset (Figure S4). Consistency is
observed both for expression differences in epithelial and stro-
mal components.
Switch from Adipose to Fibrous Stroma Supports
Oxidative Metabolism in Cancerous Cells
Tumor cells are often more glycolytic than their normal counter-
parts even in the presence of oxygen. This phenomenon is known
as theWarburg effect (Wallace, 2005) and is thought to occur due2082 Cell Reports 17, 2075–2086, November 15, 2016to the higher anabolic needs of highly proliferative tumor cells
(Vander Heiden et al., 2009). Consistent with this phenomenon,
we observe enrichment for glycolysis genes among those
upregulated in cancer epithelium compared to normal epithelium
(Figure 5A). However, contrary to the reduction in mitochondrial
activity in cancerous cells predicted by the Warburg effect,
we observe strong enrichment for genes involved in oxidative
phosphorylation (OXPHOS) among those upregulated in cancer
epithelium compared to normal epithelium (Figure 5A). Further-
more, upregulation both glycolysis and OXPHOS genes can be
confirmed in comparisons of gene expression profiles of tumor
versus normal breast epithelium after LCM (Figure 5A).
The upregulation of both glycolytic and oxidative pathways in
cancer cells comes with a demand for nutrients and oxygen,
which can be met both by increased angiogenesis and poten-
tially by the support of other cells in the microenvironment. The
previously proposed reverse Warburg effect model (Martinez-
Outschoorn et al., 2014, 2015; Pavlides et al., 2009) postulates
that tumor cells can induce shutdown of oxidative metabolism
in the surrounding stromal cells, causing them to reduce oxygen
consumption and to secrete high-energy metabolites produced
through glycolysis. Those metabolites may then be taken up by
cancerous cells to fuel their own oxidative metabolism. Consis-
tent with that model, we observe enrichment for OXPHOS genes
among those downregulated in tumor stroma, and for glycolysis
genes among those upregulated in the tumor stroma (Figure 5A).
Given that adipocytes have higher rates of mitochondrial
activity than fibroblasts (Hofmann et al., 2012; Wilson-Fritch
et al., 2003), the observed downregulation of OXPHOS genes
in the tumor stroma may reflect the change in stromal composi-
tion, from amore adipose (oxidative) stroma in normal breast to a
more fibrous (glycolytic) stroma in breast tumors. To determine
whether such change indeed occurs, we examined expression
levels of adipocyte (PPARG, CEBPA, ADIPOQ, and FABP4) or
CAF (ACTA2, FN1, FAP, and COL1A1) markers in the stroma of
normal breast and different breast tumor subtypes (Figure 5B).
Adipocyte markers are highly expressed in the stroma of normal
breast and Luminal A tumors, with negligible expression in other
tumor subtypes. CAF markers, in contrast, seem to display the
opposite pattern of expression. Such observations are consis-
tent with fibrosis in breast tumors, and with the higher incidence
of tumors with adipose stroma among those of the Luminal A
subtype (Jung et al., 2015). The change in stromal adipocyte
content between normal breast and breast tumor is also
apparent in H&E staining slides gathered from matched tumor/
normal samples from TCGA (Figure 5C). In the LCM dataset,
only the fibrous portion of the stroma was selected for analysis
both in normal breast and in breast tumors. Therefore, consistent
with the idea that the observed changes in stromal OXPHOS
gene expression result from a change from adipose to fibrous
stroma, no change in expression of those genes is observed in
the LCM dataset (Figure 5A).
We next asked whether the change from adipose to fibrous
stroma was associated with a change from oxidative to glyco-
lytic stroma. To examine this, we analyzed the correlation
between the expression of either adipocyte or CAF markers in
the stroma and the stromal expression of OXPHOS genes across
breast cancer subtypes. We observed that, as expected, the
stromal expression of most OXPHOS genes had a strong
positive correlation with the stromal expression of adipocyte
markers, whereas the expression of CAF markers in the stroma
was negatively correlated with OXPHOS genes (Figure 5D).
The reverse Warburg effect model predicts that a glycolytic
stroma associates with oxidative cancerous epithelial cells,
whereas an oxidative stroma would be associated with more
glycolytic tumor cells. Given that a fibrous stroma seems to be
more glycolytic than an adipose one, we hypothesized that a
change from adipose to fibrous stroma would associate with a
change from glycolytic to oxidative cancerous epithelium. We
therefore analyzed the degree of correlation between theexpression of either adipocyte or CAF markers in the stroma
and the expression of OXPHOS genes in the epithelial frac-
tion across breast cancer subtypes. Stromal expression of
CAF markers was indeed positively correlated with epithelial
OXPHOS gene expression, whereas adipocyte marker expres-
sion in the stroma was negatively correlated with OXPHOS
gene expression in the epithelial fraction (Figure 5E). Interest-
ingly, the stromal expression of CAV1, a gene whose low expres-
sion in breast cancer stroma is known to associate with negative
prognosis and with tumors with reverse Warburg metabolism
(Martinez-Outschoorn et al., 2014, 2015; Pavlides et al., 2009),
is strongly correlated with the expression of adipocyte markers
in the stroma (mean r = 0.97), providing further support for the hy-
pothesis that stromal adiposity associates negatively and the
stromal fibroblast content associates positively with the reverse
Warburg pattern of metabolism.
DISCUSSION
The EDec method provides accurate platform-independent
estimation of cell type proportions, DNA methylation profiles,
and gene expression profiles of constituent cell types. By sig-
nificantly relaxing the dependence on reference methylation
profiles of constituent cell types compared to previous methods
(Housemanet al., 2012), EDec enables deconvolution of complex
tumor tissues where highly accurate references are unavailable.
In contrast to reference-free methods (Houseman et al., 2014,
2016; Rahmani et al., 2016; Zheng et al., 2014; Zou et al.,
2014), EDec’s indirect use of surrogate references greatly assis-
ted in the interpretation of deconvolution results, allowing us to
uncover more complex biological patterns than possible by
applying other reference-free deconvolution techniques.
Furthermore, unlike previous methylation-based deconvolution
methods, EDec does not require that each cell type be explained
by a single component (e.g., cancerous epithelial fraction in the
TCGA dataset was modeled by five different components), thus
making it possible tomodel the full diversity of cancerous epithe-
lial cells. Despite such methodological advances, we note that
thecurrent tissuemodels obtainedbyEDecstill only approximate
the full complexity of breast tumors. For example, more detailed
deconvolution of individual components of the stromal and im-
mune fractions would likely yield additional biological insights.
By addressing the confounding issue of tissue heterogeneity,
EDec enables the comparison of tumors of various cell type
compositions based on inferredmolecular profiles of constitutive
cancer epithelial cells and also the comparisons between cancer
cell fractions of tumors and experimentally more tractable cell
line models. EDec reveals that methylome profiles of breast can-
cer cells are distinct from those of normal epithelial cell types,
and that they can be mapped to specific groups of cancer cell
lines. We also observe that cancerous cells of basal-like tumors
have particularly distinct cellular identity as indicated by their
distinct methylation profiles.
By providing information about the epigenomic and transcrip-
tomic states of both cancerous epithelial and non-epithelial
tumor cells, the method enables the study of heterotypic interac-
tions driving tumor progression. The most striking pattern that
emerged from our analyses is metabolic coupling betweenCell Reports 17, 2075–2086, November 15, 2016 2083
epithelium and stroma that seems to be related to the degree of
adiposity of the stroma. Specifically, upregulation of both glycol-
ysis and OXPHOS in cancerous epithelial cells supports the idea
that, despite the long-postulated Warburg effect, cancer cells in
breast tumors still upregulate their energy production through
OXPHOS in comparison to normal cells (Zu and Guppy, 2004).
Furthermore, the switch from adipose to fibrous stroma leads
to lower stromal mitochondrial activity, which in turn seems to
support upregulation of OXPHOS in cancerous epithelial cells.
Our findings therefore refine the reverse Warburg effect model
(Martinez-Outschoorn et al., 2014, 2015; Pavlides et al., 2009)
by showing that it may be mediated by changes in cell type
composition of tumor stroma. It is tempting to speculate that
the differences in stroma composition across tumor subtypes
may be related to a different capacity of distinct tumor types to
induce the conversion of adipocytes into fibroblasts (Bochet
et al., 2013; Dirat et al., 2011), which would be more
supportive of reverse Warburg metabolism. Despite these
encouraging results, which are largely confirmed by expression
profiling of microdissected tumors, further experiments focusing
on protein and metabolite levels in different tumor cell types will
be needed to conclusively confirm this model.
In conclusion, EDec reveals layers of biological information
about distinct cell types within solid tumors and about their
heterotypic interactions that were previously inaccessible at
such large scale due to tissue heterogeneity. EDec improves on
previous methods by employing a data-driven approach that
makes indirect use of reference profiles of constituent cell types
and adequately models the variability of methylation profiles
across different cancer cells.We note that EDec is a general tech-
nique and could potentially be applied to different types of tumors
andothercomplexnon-tumor tissues.However, suchapplications
would involve new feature selection with a set of references
appropriate for that tissue, andwouldneed tobevalidated. Inaddi-
tion to themethod itself, we have also developed a ‘‘deconvoluted
breast cancer’’ data resource for breast tumors and normal
breast tissues within the TCGA collection (http://genboree.org/
theCommons/projects/edec). This resource can now be further
explored by the community to derive or test new hypotheses.EXPERIMENTAL PROCEDURES
ThunderStorm BS-Seq Assay and Breast Cancer Target Panel
A set of 1,000 target regions of around 300 bp in length were preselected for
targeted bisulfite sequencing based on previous reports of their involvement
in breast cancer biology (Table S2). Of the 1,000 genomic regions, 149 were
selected based on cell type-specific methylation based on Roadmap Epige-
nomics reference DNA methylation profiles (Kundaje et al., 2015).
Primer pairs designed to specifically amplify each selected target region
were designed by RainDance Technologies. The ThunderStorm BS-seq assay
using that set of primer pairs was performed at RainDance Technologies
according to the manufacturer’s specification. In summary, that assay uses a
microfluidic chip to performmultiplex amplification of bisulfite-treatedDNA us-
ing the set of primers designed to amplify the selected set of genomic regions.
This step is followed by sequencing of PCR product. Read mapping and
methylation level calling was performed using Bismark (Krueger and Andrews,
2011). Target regions were sequenced on average to 2003 coverage. For all
subsequent analyses, DNA methylation levels for all CpGs overlapping each
of the target regions were averaged, giving an average methylation value for
each region of interest. For eight of the breast cancer samples profiled using2084 Cell Reports 17, 2075–2086, November 15, 2016this assay, 450k arrays were also performed by the TCGA group. We observed
over 0.9 correlation between methylation levels measured by both platforms
over the 614 regions overlapping 450k array probes for all samples analyzed.
TCGA Data Processing
Methylation Array Data
The breast cancer TCGA DNA methylation data were generated using either
the Infinium HumanMethylation450 BeadChip (450k array) or the Infinium
HumanMethylation27 BeadChip (27k array). We used the TCGA Assembler
(Zhu et al., 2014) to download level 3 data (fully processed) for all 27k and
450k profiles. Because most 27k probes are present in the 450k array, we
merged the two datasets and included only overlapping probes in our analysis.
We also removed any probe with a detection p value less than 0.05 in at least
one sample, those that overlapped known SNPs, and those that were previ-
ously reported as cross reactive (Chen et al., 2013). The final number of probes
passing these criteria was 17,907. We also corrected for platform biases using
an Empirical Bayes-based approach (ComBat) (Johnson et al., 2007), imple-
mented in the SVA package in R (Leek et al., 2015).
RNA-Sequencing Data
TCGA Assembler (Zhu et al., 2014) was used to download normalized (RNA
sequencing [RNA-seq] v2RNA-seq by expectationmaximization) gene tran-
script abundance measurements from the TCGA database. PAM50 classifica-
tion (Parker et al., 2009) based on RNA-seq for 1,030 breast cancer samples
generated by the TCGA Analysis Working Group were obtained from the Uni-
versity of California, Santa Cruz (UCSC), Cancer Genomics Browser (Goldman
et al., 2013). Of the TCGA breast cancer samples that had RNA-sequencing
data and associated PAM50 classification, 1,005 also had DNA methylation
data. For normal breast samples, 100 had both DNA methylation and RNA-
sequencing data. Therefore, the final set of RNA-sequencing samples con-
tained 1,105 samples.
Code and Dataset Availability
The EDec software is available as an R package. It can be downloaded from
https://github.com/BRL-BCM/EDec. Documentation and usage examples
are also available on that same page. All datasets associated with this publica-
tion can be found at http://genboree.org/theCommons/projects/edec. Primary
human breast tumor tissue and adjacent normal tissue were obtained with
local Institutional Review Board (IRB# PRO11090404) from the University of
Pittsburgh’s Health Science Tissue Bank.
ACCESSION NUMBERS
The accession number for the targeted bisulfite sequencing data reported in
this paper is GEO: GSE87297.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at http://
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